Leidos awarded NIAID contract to support biomedical research

Published on : Published by : BioBuzz Media

Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to provide biomedical preclinical and development capabilities to support the National Institute of Allergy and Infectious Diseases (NIAID). The seven-year, multi-award, indefinite delivery/indefinite quantity contract has an approximate value of up to $545 million across all task areas to be engaged on this program. This project will be funded in whole or in part with federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021D00030.

ATCC Wins $545 Million Contract to Respond to Emerging Infectious Disease Threats

Headshot of Joseph Leonelli, SVP of ATCC Federal Solutions
Published on : Published by : Alex Keown

As the world continues to grapple with the ongoing COVID-19 pandemic and the emergence of the new omicron variant, Virginia’s ATCC secured a seven-year Delivery/Indefinite Quantity (IDIQ) contract from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, valued at up to $545 million.

Seven Public Cell Therapy Companies Delivering Opportunities for Investors and Patients

Published on : Published by : Alex Keown

Cell therapies have grown to become a prevailing field dominating new medical breakthroughs with the promise of treatments and cures for multiple diseases. The biopharma hubs of Philadelphia and Maryland have emerged as important drivers of this new wave of medicine, build on the foundation of renowned research institutes, universities, and a number of successful cell therapy companies who have paved the way forward in this field.

Rockville’s Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease

Published on : Published by : BioBuzz Media

Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease (MVD). MVD is caused by either of two marburgviruses, Marburg virus and Ravn virus, and has reemerged several times since it was initially described in 1967. IBT-T03H, discovered in collaboration with the University of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.

ATCC Announces Award of HIV Reagent Program

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines and microorganisms.
Published on : Published by : Alex Keown

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.

Five Companies Edging Closer to SARS-CoV-2 Vaccine Emergency Use Authorization

Published on : Published by : Steven Surdez

Global COVID-19 cases have been spiking in Europe and the U.S. as the predicted second wave is hitting communities hard, applying new pressure on hospital capacity and forcing local and state governments to once again tighten restrictions.